One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2021-146228
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 3 |
Affiliation: Peter MacCallum Cancer Centre, Royal Melbourne Hospital, The Ohio State University, St James's University Hospital, Vita-Salute San Raffaele University, Amsterdam University Medical Centers, Jacksonville College, Mayo Clinic, Presbyterian Hospital, New York Hospital Queens, NewYork–Presbyterian Hospital, Cornell University, University of California, Irvine Medical Center, Dana-Farber Cancer Institute, University of Pennsylvania, University of Ulm, AstraZeneca (Japan), AstraZeneca (United States), The Maria Sklodowska-Curie National Research Institute of Oncology
Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
